Your browser doesn't support javascript.
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
Centonze, Diego; Rocca, Maria A; Gasperini, Claudio; Kappos, Ludwig; Hartung, Hans-Peter; Magyari, Melinda; Oreja-Guevara, Celia; Trojano, Maria; Wiendl, Heinz; Filippi, Massimo.
  • Centonze D; Department of Systems Medicine, Tor Vergata University, Rome, Italy.
  • Rocca MA; Unit of Neurology, IRCCS Neuromed, Pozzilli (IS), Italy.
  • Gasperini C; MS Center and Neurology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.
  • Kappos L; Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Hartung HP; Vita-Salute San Raffaele University, Milan, Italy.
  • Magyari M; Department of Neurosciences, San Camillo Forlanini Hospital, Rome, Italy.
  • Oreja-Guevara C; MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research and Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland.
  • Trojano M; Department of Neurology, Medical Faculty, Heinrich-Heine University, University Hospital Duesseldorf, Düsseldorf, Germany.
  • Wiendl H; Brain and Mind Centre, University of Sydney, Sydney, Australia.
  • Filippi M; Department of Neurology, Medical University of Vienna, Wien, Austria.
J Neurol ; 268(11): 3961-3968, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1176353
ABSTRACT
Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic. The disease is caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), an RNA beta coronavirus phylogenetically similar to SARS coronavirus. To date, more than 132 million cases of COVID19 have been recorded in the world, of which over 2.8 million were fatal ( https//coronavirus.jhu.edu/map.html ). A huge vaccination campaign has started around the world since the end of 2020. The availability of vaccines has raised some concerns among neurologists regarding the safety and efficacy of vaccination in patients with multiple sclerosis (MS) taking immunomodulatory or immunosuppressive therapies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Topics: Vaccines Limits: Humans Language: English Journal: J Neurol Year: 2021 Document Type: Article Affiliation country: S00415-021-10545-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Topics: Vaccines Limits: Humans Language: English Journal: J Neurol Year: 2021 Document Type: Article Affiliation country: S00415-021-10545-2